Metaraminol
Trade name
Aramine, Metaraminol ARX, Metaraminol GH Pharma, Metaraminol (Juno), Metaraminol MYX, Metaraminol (Phebra), Metaraminol Torbay
Strength
Ampoule or vial:
0.5 mg/mL (volume: 5 mL, 6 mL, 10 mL)
10 mg/mL (volume: 1 mL)
Prefilled syringe:
2.5 mg/5 mL
5 mg/10 mL
IV administration
For IV injection:
0.5 mg/mL strength:
Give undiluted.
For doses less than 1 mg, further dilution may be necessary. Withdraw 2 mL of metaraminol 0.5 mg/mL and dilute in 10 mL of compatible fluid to make a concentration of 100 microgram/mL OR refer to relevant local guideline.
10 mg/mL strength:
Dilute to 500 microgram/mL for IV injection. May be administered undiluted in larger patients in emergencies under extreme care.
For IV infusion:
Dilute to 200 microgram/mL or weaker and give via a central line or large peripheral vein.
Maximum concentration if necessary: 1 mg/mL.
Other routes of administration
10 mg/mL strength only:
IM: Suitable. Effects can be less predictable than using the IV route.
SC: Not recommended.
Compatible IV fluids
Metaraminol 1 mg/mL or weaker ampoule or vial:
Glucose 5%
Sodium chloride 0.9%
Metaraminol 200 microgram/mL or weaker (Aramine, ARX, GH Pharma, Phebra):
Hartmann's
Ringer's
Y-site only and metaraminol in glucose 5% or sodium chloride 0.9%:
Potassium chloride 20 mmol/L
Y-site only and metaraminol 200 microgram/mL or weaker:
Plasma-Lyte 148
Additional information
Extravasation risk.
Some formulations contain sulphites: Observe closely for anaphylactic reactions.
Continuous cardiac monitoring required during administration.
Taper the infusion slowly when discontinuing treatment; abrupt discontinuation may cause an excessive blood pressure response.
Aramine and Metaraminol (Phebra): Solution should be clear and colourless to slightly yellow/pink.
Discard any unused vial contents.
Protect from light during storage.